Amarin Vascepa FDA Panel Live Blog

 

BEDMINSTER, NJ ( TheStreet) -- Welcome to the live blog covering today's FDA advisory panel for Amarin's ( AMRN) prescription fish-oil pill Vascepa.

Amarin is seeking expanded use of Vascepa to treat patients with mixed dyslipidemia. a person with mixed dyslipidemia is taking a cholesterol-lowering statin to lower LDL or "bad" cholesterol but still has moderately elevated levels of triglycerides, a fatty substance found in blood. People with mixed dyslipidemia are believed to be at higher risk for cardiovascular disease.

A preview of today's FDA panel, including an explanation of the issues to be discussed and voted upon, can be found here.

Trading in Amarin shares will be halted for the duration of the FDA advisory panel.

Experts on the advisory panel will vote today on whether or not to recommend the expanded use of Vascepa. The ultimate approval decision, however, wrests with FDA and is expected to be announced on Dec. 20.

Feel free to post questions and comments during the live blog. I'll try to respond to as many as I can.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

10 Key Takeaways From Google's Solid Earnings Report

10 Key Takeaways From Google's Solid Earnings Report

Amazon Is as Well-Positioned as Anyone to Create a Popular Home Robot

Amazon Is as Well-Positioned as Anyone to Create a Popular Home Robot

Bitcoin Today: Prices Flirt With $9,000 After Weekend Boom

Bitcoin Today: Prices Flirt With $9,000 After Weekend Boom

Tech Stocks Have You Baffled? Educate Yourself in Some Portfolio Diversification

Tech Stocks Have You Baffled? Educate Yourself in Some Portfolio Diversification

Halliburton Rises Slightly After Revenue Jump

Halliburton Rises Slightly After Revenue Jump